The mGlu5 NAM mechanism is well characterized in preclinical studies and has shown therapeutic promise in clinical proof-of-concept trials for conditions such as fragile X syndrome, anxiety disorders, Parkinson’s disease dyskinesias, neuropathic pain, migraine pain, and gastroesophageal reflux disease (GERD). This evidence concerns the gene GRM5 and gastroesophageal reflux disease.